Cargando…
High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer
BACKGROUND: Increasing evidence indicates that the TGFβ/Smad signaling pathway plays a prominent role in tumor initiation, progression, and metastasis. Therefore, we investigate the expression of p-Smad2 in surgical resection specimens from non-small cell lung cancer, and evaluate the prognostic sig...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230723/ https://www.ncbi.nlm.nih.gov/pubmed/25373709 http://dx.doi.org/10.1186/1477-7819-12-328 |
_version_ | 1782344320664207360 |
---|---|
author | Chen, Yongbing Xing, Pengfei Chen, Yuanyuan Zou, Li Zhang, Yongsheng Li, Feng Lu, Xueguan |
author_facet | Chen, Yongbing Xing, Pengfei Chen, Yuanyuan Zou, Li Zhang, Yongsheng Li, Feng Lu, Xueguan |
author_sort | Chen, Yongbing |
collection | PubMed |
description | BACKGROUND: Increasing evidence indicates that the TGFβ/Smad signaling pathway plays a prominent role in tumor initiation, progression, and metastasis. Therefore, we investigate the expression of p-Smad2 in surgical resection specimens from non-small cell lung cancer, and evaluate the prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells for patients with clinical stage I to IIIA non-small cell lung cancer. METHODS: The immunohistochemical expression of p-Smad2 was evaluated in 78 formalin-fixed paraffin-embedded surgical resection specimens from clinical stage I to IIIA non-small cell lung cancer. Correlations between p-Smad2 expression and clinicopathologic characteristics were determined by Chi-square test. The prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells with regard to overall survival was determined by Kaplan-Meier. RESULTS: There were 38.5% (30/78) and 92.3% (72/78) patients with high p-Smad2 expression in stromal fibroblasts and cancer cells, respectively. There was a positive correlation between the p-Smad2 expression level in stromal fibroblasts and the p-Smad2 expression level in cancer cells (χ(2) = 4.176, P =0.045). No significant correlation of p-Smad2 expression in stromal fibroblasts or cancer cells with any of clinicopathologic characteristics was found. The 3-year overall survival rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and 37.7%, respectively (χ(2) = 3.86, P = 0.049). No significant association was found between low and high p-Smad2 expression in cancer cells with respect to overall survival, respectively (χ(2) = 0.34, P =0.562). CONCLUSIONS: The results suggested that high p-Smad2 expression in stromal fibroblasts predicted poor survival in patients with clinical stage I to IIIA non-small cell lung cancer. |
format | Online Article Text |
id | pubmed-4230723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42307232014-11-14 High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer Chen, Yongbing Xing, Pengfei Chen, Yuanyuan Zou, Li Zhang, Yongsheng Li, Feng Lu, Xueguan World J Surg Oncol Research BACKGROUND: Increasing evidence indicates that the TGFβ/Smad signaling pathway plays a prominent role in tumor initiation, progression, and metastasis. Therefore, we investigate the expression of p-Smad2 in surgical resection specimens from non-small cell lung cancer, and evaluate the prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells for patients with clinical stage I to IIIA non-small cell lung cancer. METHODS: The immunohistochemical expression of p-Smad2 was evaluated in 78 formalin-fixed paraffin-embedded surgical resection specimens from clinical stage I to IIIA non-small cell lung cancer. Correlations between p-Smad2 expression and clinicopathologic characteristics were determined by Chi-square test. The prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells with regard to overall survival was determined by Kaplan-Meier. RESULTS: There were 38.5% (30/78) and 92.3% (72/78) patients with high p-Smad2 expression in stromal fibroblasts and cancer cells, respectively. There was a positive correlation between the p-Smad2 expression level in stromal fibroblasts and the p-Smad2 expression level in cancer cells (χ(2) = 4.176, P =0.045). No significant correlation of p-Smad2 expression in stromal fibroblasts or cancer cells with any of clinicopathologic characteristics was found. The 3-year overall survival rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and 37.7%, respectively (χ(2) = 3.86, P = 0.049). No significant association was found between low and high p-Smad2 expression in cancer cells with respect to overall survival, respectively (χ(2) = 0.34, P =0.562). CONCLUSIONS: The results suggested that high p-Smad2 expression in stromal fibroblasts predicted poor survival in patients with clinical stage I to IIIA non-small cell lung cancer. BioMed Central 2014-11-05 /pmc/articles/PMC4230723/ /pubmed/25373709 http://dx.doi.org/10.1186/1477-7819-12-328 Text en © Chen et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Chen, Yongbing Xing, Pengfei Chen, Yuanyuan Zou, Li Zhang, Yongsheng Li, Feng Lu, Xueguan High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer |
title | High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer |
title_full | High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer |
title_fullStr | High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer |
title_full_unstemmed | High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer |
title_short | High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer |
title_sort | high p-smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage i to iiia non-small cell lung cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230723/ https://www.ncbi.nlm.nih.gov/pubmed/25373709 http://dx.doi.org/10.1186/1477-7819-12-328 |
work_keys_str_mv | AT chenyongbing highpsmad2expressioninstromalfibroblastspredictspoorsurvivalinpatientswithclinicalstageitoiiianonsmallcelllungcancer AT xingpengfei highpsmad2expressioninstromalfibroblastspredictspoorsurvivalinpatientswithclinicalstageitoiiianonsmallcelllungcancer AT chenyuanyuan highpsmad2expressioninstromalfibroblastspredictspoorsurvivalinpatientswithclinicalstageitoiiianonsmallcelllungcancer AT zouli highpsmad2expressioninstromalfibroblastspredictspoorsurvivalinpatientswithclinicalstageitoiiianonsmallcelllungcancer AT zhangyongsheng highpsmad2expressioninstromalfibroblastspredictspoorsurvivalinpatientswithclinicalstageitoiiianonsmallcelllungcancer AT lifeng highpsmad2expressioninstromalfibroblastspredictspoorsurvivalinpatientswithclinicalstageitoiiianonsmallcelllungcancer AT luxueguan highpsmad2expressioninstromalfibroblastspredictspoorsurvivalinpatientswithclinicalstageitoiiianonsmallcelllungcancer |